Serum NOX1 and Raftlin as New Potential Biomarkers of Interest in Schizophrenia: A Preliminary Study

References

• Goff DC. The pharmacologic treatment of schizophrenia—2021. JAMA. 2021;325(2):175–176. doi:10.1001/jama.2020.19048
   Web of Science ®Google Scholar
• Jauhar S, Johnstone M, McKenna PJ. Schizophrenia. Lancet. 2022;399(10323):473–486. doi:10.1016/S0140-6736(21)01730-X
   PubMed Web of Science ®Google Scholar
• Anderson G, Berk M, Dodd S, et al. Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:1–4. doi:10.1016/j.pnpbp.2012.10.008
   PubMed Web of Science ®Google Scholar
• Simpson DS, Oliver PL. ROS generation in microglia: understanding oxidative stress and inflammation in neurodegenerative disease. Antioxidants. 2020;9(8):743. doi:10.3390/antiox9080743
   Web of Science ®Google Scholar
• Murray AJ,Rogers JC, Katshu MZ, Liddle PF, Upthegrove R. Oxidative stress and the pathophysiology and symptom profile of schizophrenia spectrum disorders. Front Psychiatry. 2021;2021:1235.
   Google Scholar
• Ermakov EA, Dmitrieva EM, Parshukova DA, Kazantseva DV, Vasilieva AR, Smirnova LP. Oxidative stress-related mechanisms in schizophrenia pathogenesis and new treatment perspectives. Oxid Med Cell Longev. 2021;2021:1.
   Web of Science ®Google Scholar
• Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry. 2014;27(3):185. doi:10.1097/YCO.0000000000000054
   PubMed Web of Science ®Google Scholar
• Bedard K, Krause K-H. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87(1):245–313. doi:10.1152/physrev.00044.2005
   PubMed Web of Science ®Google Scholar
• Sorce S, Krause K-H, Jaquet V. Targeting NOX enzymes in the central nervous system: therapeutic opportunities. Cell Mol Life Sci. 2012;69(14):2387–2407. doi:10.1007/s00018-012-1014-5
   Web of Science ®Google Scholar
• Schiavone S, Jaquet V, Sorce S, et al. NADPH oxidase elevations in pyramidal neurons drive psychosocial stress-induced neuropathology. Transl Psychiatry. 2012;2(5):e111–e111. doi:10.1038/tp.2012.36
   Web of Science ®Google Scholar
• Schiavone S, Camerino GM, Mhillaj E, et al. Visceral fat dysfunctions in the rat social isolation model of psychosis. Front Pharmacol. 2017;8:787. doi:10.3389/fphar.2017.00787
   Web of Science ®Google Scholar
• Miller BJ, Goldsmith DR. Evaluating the hypothesis that schizophrenia is an inflammatory disorder. Focus. 2020;18(4):391–401. doi:10.1176/appi.focus.20200015
   Google Scholar
• Najjar S, Pearlman DM. Neuroinflammation and white matter pathology in schizophrenia: systematic review. Schizophr Res. 2015;161(1):102–112. doi:10.1016/j.schres.2014.04.041
   PubMed Web of Science ®Google Scholar
• Müller N, Weidinger E, Leitner B, et al. The role of inflammation in schizophrenia. Front Neurosci. 2015;9:372. doi:10.3389/fnins.2015.00372
   PubMed Web of Science ®Google Scholar
• Anderson G, Maes M, Berk M. Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathways. Prog Neuropsychopharmacol Biol Psychiatry. 2013;42:101–114. doi:10.1016/j.pnpbp.2012.07.016
   PubMed Web of Science ®Google Scholar
• Lucero HA, Robbins PW. Lipid rafts–protein association and the regulation of protein activity. Arch Biochem Biophys. 2004;426(2):208–224. doi:10.1016/j.abb.2004.03.020
   PubMed Web of Science ®Google Scholar
• Saeki K, Miura Y, Aki D, Kurosaki T, Yoshimura A. The B cell‐specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction. EMBO J. 2003;22(12):3015–3026. doi:10.1093/emboj/cdg293
   PubMed Web of Science ®Google Scholar
• Lee W, Yoo H, Ku S-K, et al. Raftlin: a new biomarker in human sepsis. Inflammation. 2014;37(3):706–711. doi:10.1007/s10753-013-9788-7
   PubMed Web of Science ®Google Scholar
• Bilal N, Kurutas EB, Orhan I, et al. Evaluation of preoperative and postoperative serum interleukin-6, interleukin-8, tumor necrosis factor α and raftlin levels in patients with obstructive sleep apnea. Sleep Breath. 2021;25(2):819–826. doi:10.1007/s11325-020-02161-7
   Web of Science ®Google Scholar
• Zhu Y, Gumlaw N, Karman J, et al. Lowering glycosphingolipid levels in CD4+ T cells attenuates T cell receptor signaling, cytokine production, and differentiation to the Th17 lineage. J Biol Chem. 2011;286(17):14787–14794. doi:10.1074/jbc.M111.218610
   Web of Science ®Google Scholar
• Bilgen F, Ural A, Kurutas EB, et al. The effect of oxidative stress and Raftlin levels on wound healing. Int Wound J. 2019;16(5):1178–1184. doi:10.1111/iwj.13177
   PubMed Web of Science ®Google Scholar
• Saeki K, Fukuyama S, Ayada T, et al. A major lipid raft protein raftlin modulates T cell receptor signaling and enhances th17-mediated autoimmune responses. J Immunol. 2009;182(10):5929–5937. doi:10.4049/jimmunol.0802672
   Web of Science ®Google Scholar
• Debnath M, Berk M. Th17 pathway–mediated immunopathogenesis of schizophrenia: mechanisms and implications. Schizophr Bull. 2014;40(6):1412–1421. doi:10.1093/schbul/sbu049
   PubMed Web of Science ®Google Scholar
• Hursitoglu O, Kurutas EB. Serum levels of 8-iso-prostaglandin F2α and Raftlin in patients with generalized anxiety disorder. Clin Psychopharmacol Neurosci. 2022;2022:1.
   Google Scholar
• Fraguas D, Díaz-Caneja CM, Ayora M, et al. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull. 2019;45(4):742–751. doi:10.1093/schbul/sby125
   PubMed Web of Science ®Google Scholar
• Zhang M, Zhao Z, He L, et al. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci. 2010;53(1):112–124. doi:10.1007/s11427-010-0013-8
   PubMed Web of Science ®Google Scholar
• First MB. Structured clinical interview for the DSM (SCID). Ency Clin Psychol. 2014;2014:1–6.
   Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary depression scale. Br J Psychiatry. 1993;163(S22):39–44. doi:10.1192/S0007125000292581
   Web of Science ®Google Scholar
• Madireddy S, Madireddy S. Regulation of reactive oxygen species-mediated damage in the pathogenesis of schizophrenia. Brain Sci. 2020;10(10):742. doi:10.3390/brainsci10100742
   Web of Science ®Google Scholar
• D’souza B, D’souza V. Oxidative injury and antioxidant vitamins E and C in schizophrenia. Indian J Clin Biochem. 2003;18(1):87–90. doi:10.1007/BF02867671
   Google Scholar
• Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of ω-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophr Res. 2003;62(3):195–204. doi:10.1016/S0920-9964(02)00284-0
   PubMed Web of Science ®Google Scholar
• Boskovic M, Vovk T, Kores Plesnicar B, et al. Oxidative stress in schizophrenia. Curr Neuropharmacol. 2011;9(2):301–312. doi:10.2174/157015911795596595
   PubMed Web of Science ®Google Scholar
• Schiavone S, Mhillaj E, Neri M, et al. Early loss of blood-brain barrier integrity precedes NOX2 elevation in the prefrontal cortex of an animal model of psychosis. Mol Neurobiol. 2017;54(3):2031–2044. doi:10.1007/s12035-016-9791-8
   PubMed Web of Science ®Google Scholar
• Colaianna M, Schiavone S, Zotti M, et al. Neuroendocrine profile in a rat model of psychosocial stress: relation to oxidative stress. Antioxid Redox Signal. 2013;18(12):1385–1399. doi:10.1089/ars.2012.4569
   PubMed Web of Science ®Google Scholar
• Singh P, Agnihotri SK, Tewari MC, et al. HIV-1 nef breaches placental barrier in rat model. PLoS One. 2012;7(12):e51518. doi:10.1371/journal.pone.0051518
   PubMed Web of Science ®Google Scholar
• Goldsmith D, Rapaport M, Miller B. A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry. 2016;21(12):1696–1709. doi:10.1038/mp.2016.3
   PubMed Web of Science ®Google Scholar
• Al-Hakeim HK, Al-Rammahi DA, Al-Dujaili AH. IL-6, IL-18, sIL-2R, and TNFα proinflammatory markers in depression and schizophrenia patients who are free of overt inflammation. J Affect Disord. 2015;182:106–114. doi:10.1016/j.jad.2015.04.044
   PubMed Web of Science ®Google Scholar
• Luo Y, He H, Zhang M, et al. Elevated serum levels of TNF-α, IL-6 and IL-18 in chronic schizophrenic patients. Schizophr Res. 2014;159(2–3):556–557. doi:10.1016/j.schres.2014.09.015
   Web of Science ®Google Scholar
• Ding M, Song X, Zhao J, et al. Activation of Th17 cells in drug naïve, first episode schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2014;51:78–82. doi:10.1016/j.pnpbp.2014.01.001
   PubMed Web of Science ®Google Scholar
• Borovcanin M, Jovanovic I, Radosavljevic G, et al. Elevated serum level of type-2 cytokine and low IL-17 in first episode psychosis and schizophrenia in relapse. J Psychiatr Res. 2012;46(11):1421–1426. doi:10.1016/j.jpsychires.2012.08.016
   PubMed Web of Science ®Google Scholar
• Petrikis P, Voulgari PV, Tzallas AT, et al. Cytokine profile in drug-naïve, first episode patients with psychosis. J Psychosom Res. 2015;79(4):324–327. doi:10.1016/j.jpsychores.2015.06.011
   Web of Science ®Google Scholar
• Dimitrov DH, Lee S, Yantis J, et al. Differential correlations between inflammatory cytokines and psychopathology in veterans with schizophrenia: potential role for IL-17 pathway. Schizophr Res. 2013;151(1–3):29–35. doi:10.1016/j.schres.2013.10.019
   Web of Science ®Google Scholar
• Güneş M, Bulut M, Demir S, et al. Diagnostic performance of increased prolidase activity in schizophrenia. Neurosci Lett. 2016;613:36–40. doi:10.1016/j.neulet.2015.12.036
   PubMed Web of Science ®Google Scholar
• Hurşitoğlu O, Orhan FÖ, Kurutaş EB, et al. Diagnostic performance of increased malondialdehyde level and oxidative stress in patients with schizophrenia. Arch Neuropsychiatry. 2021;58(3):184. doi:10.29399/npa.27372
   Google Scholar
• Prossnitz ER, Barton M. The G-protein-coupled estrogen receptor GPER in health and disease. Nat Rev Endocrinol. 2011;7(12):715–726. doi:10.1038/nrendo.2011.122
   PubMed Web of Science ®Google Scholar
• Hursitoglu O, Orhan FO, Kurutas EB, Doganer A, Durmus HT, Bozkusc O. Evaluation serum levels of g protein-coupled estrogen receptor and its diagnostic value in patients with schizophrenia. Memory. 2020;33:34.
   Google Scholar
• Meyer MR, Barton M. GPER blockers as Nox downregulators: a new drug class to target chronic non-communicable diseases. J Steroid Biochem Mol Biol. 2018;176:82–87. doi:10.1016/j.jsbmb.2017.03.019
   Web of Science ®Google Scholar